Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor

H Fechner1,6, S Pinkert1,6, X Wang1, I Sipo1, L Suckau1, J Kurreck2, A Dörner1, K Sollerbrant3, H Zeichhardt4, H-P Grunert4, R Vetter5, H-P Schultheiss1 and W Poller1

1Department of Cardiology and Pneumology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, Germany; 2Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany; 3Ludwig Institute for Cancer Research, Stockholm Branch, Karolinska Institute, Stockholm, Sweden; 4Department of Virology, Institute of Infectious Diseases, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, Germany and 5Institute of Clinical Pharmacology and Toxicology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, Germany

As coxsackievirus B3 (CoxB3) and adenoviruses may cause acute myocarditis and inflammatory cardiomyopathy, isolation of the common coxsackievirus–adenovirus-receptor (CAR) has provided an interesting new target for molecular antiviral therapy. Whereas many viruses show high mutation rates enabling them to develop escape mutants, mutations of their cellular virus receptors are far less likely. We report on antiviral efficacies of CAR gene silencing by short hairpin (sh)RNAs in the cardiac-derived HL-1 cell line and in primary neonatal rat cardiomyocytes (PNCMs). Treatment with shRNA vectors mediating RNA interference against the CAR resulted in almost complete silencing of receptor expression both in HL-1 cells and PNCMs. Whereas CAR was silenced in HL-1 cells as early as 24 h after vector treatment, its downregulation in PNCMs did not become significant before day 6. CAR knockout resulted in inhibition of CoxB3 infections by up to 97% in HL-1 cells and up to 90% in PNCMs. Adenovirus was inhibited by only 75% in HL-1 cells, but up to 92% in PNCMs. We conclude that CAR knockout by shRNA vectors is efficient against CoxB3 and adenovirus in primary cardiac cells, but the efficacy of this approach in vivo may be influenced by cell type-specific silencing kinetics in different tissues.

Gene Therapy (2007) 14, 960–971; doi:10.1038/sj.gt.3302948; published online 22 March 2007

Keywords: viral cardiomyopathy; coxsackievirus–adenovirus-receptor; RNA interference; gene silencing; adenovirus vector

Introduction

Initially, cardiac viral infections were documented in the clinical context of acute myocarditis. Coxsackievirus B3 (CoxB3) was the first virus detected in this condition in humans,1 and adenoviruses of serotypes 2 and 5 were later described as common agents of myocarditis in children.2 Systematic screening of patients with dilated cardiomyopathy has recently revealed that a rather broad spectrum of viruses may also chronically persist in human myocardium.3 It is therefore assumed that acute cardiac viral infections may cause not only acute illness, but also chronic heart disease if not definitely eliminated from the heart.4 The disease may progress to terminal heart failure and then require heart transplantation as a last therapeutic option.

RNA interference (RNAi) is a process of posttranscriptional gene silencing mediated by double-stranded RNA (dsRNA). The introduction of double-stranded small interfering RNAs (siRNA) or vectors expressing short hairpin RNA (shRNA) has already been successfully used to inhibit the replication of multiple viruses in vitro and in vivo including respiratory viruses,5 hepatitis B6,7 and C viruses,8 foot-and-mouth disease virus,9 human herpesvirus-6,10 cytomegalovirus,11 SARS coronavirus,12 HIV-113 and CoxB3.14,15 However, the efficiency of RNAi depends on exact homology of the siRNA to the target sequence. A single mismatch can be sufficient to abrogate silencing by RNAi.16

Many RNA viruses encode polymerase enzymes that lack proofreading abilities and, as a result, have high mutation rates. Thus, there is a high probability that viruses will rapidly develop resistance to a particular siRNA during virus replication by incorporation of nucleotide mutations within the target sequence of the siRNA. Thus, it has been shown that hepatitis C virus becomes resistant against a particular siRNA after several cycles of replication by the incorporation of point mutations within the siRNA target sequence.17 Similar
data have been reported for HIV-1\textsuperscript{18} and poliovirus infections.\textsuperscript{19} Therefore, therapeutic targeting of non-variable virus-binding receptors on susceptible cells or other host cell molecules directly or indirectly involved in virus infections is an interesting alternative to targeting of the virus itself.\textsuperscript{15,20–25} One approach of this type showed that downregulation of the CD4-independent attachment receptor (DC-SIGN) significantly inhibited HIV infection of dendritic cells (DC) and prevented the transfer of infectious HIV-1 particles from DC to T cells.\textsuperscript{22}

Adenoviruses of types 2 and 5 and CoxB3 use the coxsackievirus–adenovirus-receptor (CAR) to infect their target cells, either for virus attachment (adenoviruses) or virus internalization (CoxB3).\textsuperscript{26} Therefore, CAR represents an attractive target for the inhibition of cardiac CoxB3 and adenovirus infections. It has been shown recently that suppression of CAR by RNAi results in inhibition of CoxB3 infections.\textsuperscript{15,27} These studies were carried out with cells of non-cardiac origin, and chemically synthesized siRNAs were used to inhibit CAR expression. However, the therapeutic use of synthetic siRNAs is significantly limited by their rapid degradation in target cells resulting in only transient gene silencing.\textsuperscript{28} Moreover, most cells of cardiac origin are very difficult to transfect with chemically synthesized siRNAs even in vitro. These problems are significantly aggravated in vivo. Despite intense efforts during recent years, systemic and target organ-specific delivery of siRNAs remains a major hurdle for in vivo applications of RNAi.

Therefore, we investigated the antiviral potential of CAR gene silencing in cells of cardiac origin by use of newly developed adenoviral vectors (AdVs) that generate shRNA against murine or rat CAR (shCAR).

shCAR treatment of HL-1 cells and primary neonatal rat cardiomyocytes (PNCMs) led to almost complete silencing of CAR gene expression and efficient inhibition of CoxB3 infection in both cell types, whereas efficient inhibition of adenovirus infections was observed only in the primary cells. The studies thus indicate cell type-specific responses of cellular CAR to shCAR treatment, which need to be considered as important determinants of this new antiviral approach in vivo.

Results

Selection and specificity of mouse CAR shRNAs
To investigate the efficacy of CAR silencing for the inhibition of adenovirus and CoxB3 infection in cardiac HL-1 cells, we generated a total of three shRNAs (shCAR2\textsubscript{m}, shCAR3\textsubscript{m}, shCAR4\textsubscript{m}) directed against the extracellular domains of the mCAR splice variants mCAR-1\textsuperscript{29} and mCAR-2\textsuperscript{20} (Figure 1) following published siRNA selection criteria.\textsuperscript{30} DNA oligonucleotides encoding these shRNAs were then cloned into expression plasmids under the control of a murine RNA polymerase III U6 promoter. To test their efficacies, we co-transfected 293T cells with shCAR2\textsubscript{m}, shCAR3\textsubscript{m} or shCAR4\textsubscript{m} expressing plasmid, together with plasmids expressing recombinant mCAR1 and mCAR2. As a transfection control, a plasmid expressing an irrelevant shRNA was used. To determine the extent of recombinant mCAR1- and mCAR2-mRNA downregulation, total cellular RNA was isolated 48 h after transfection and Northern blot hybridization was carried out. These experiments showed that two shRNAs were highly efficient: shCAR2\textsubscript{m}, with 93% silencing and shCAR4\textsubscript{m}, with 97% silencing of mCAR1- and mCAR2-mRNA. The control
shRNA affected neither mCAR1- nor mCAR2-mRNA expression (Figure 2a).

To analyze the specificities of shCAR2m and shCAR4m, both were also tested for downregulation of human CAR (hCAR) by co-transfection with a plasmid expressing recombinant soluble hCAR. None of the mouse CAR-specific shRNAs influenced hCAR-mRNA expression. In contrast, a human-specific shRNA efficiently silenced hCAR-mRNA expression (Figure 2b). Considering that shCAR2m has only one mismatch and shCAR4m three mismatches as compared to hCAR-mRNA, these experiments indicate very high species specificity of the selected mCAR-shRNAs.

Silencing of mCAR in mouse cardiac HL-1 cells

To determine the optimal AdV dose for transduction of mouse cardiac HL-1 cells, we first transduced HL-1 cells with a GFP-expressing marker AdV at a multiplicity of infection (MOI) from 5 to 1000. At an MOI from 60 to 100, GFP expression was seen in 76–80% of the cells, whereas no cytotoxic effects were observed. Further dose escalation resulted in an only slight further increase of transduction rate (Figure 3a), and at an MOI of 500 or higher, cytotoxic effects became evident (increase of apoptotic cells, reduction of cell growth). HL-1 cells express mCAR1 but no mCAR2 on their cell surface (not shown). Therefore, the silencing capacity of the new AdshCAR4m (Figure 1), which expresses the above-evaluated most efficient shCAR4m, was investigated with respect to mCAR1 expression in HL-1 cells only. To assess the amount of AdV-generated shCAR4m, HL-1 cells were transduced with AdshCAR4m at an MOI from 5 to 1000. The expression of shCAR4m was analyzed 24, 48 and 72 h later. A time- and dose-dependent transcription of shCAR4m, was detected (Figure 3b). As a consequence of shRNA expression, strong downregulation of mCAR1-mRNA was observed 48 and 72 h after transduction. Near maximal reduction of 85–90% was observed at an MOI of 100. Higher doses did not result in...
significant further downregulation of mCAR1-mRNA (Figure 3c). These results indicate that an MOI of 100 was optimal for HL-1 transduction, as this dose allowed strong downregulation of mCAR1-mRNA in HL-1 cells, although cytotoxicity of the viral vector was still very low.

We next investigated mCAR1 protein expression after transduction of HL-1 cells with AdshCAR4m at an MOI of 100. To disrupt pre-existing membrane-associated mCAR1, HL-1 cells were trypsinized 24 h after AdshCAR4m transduction and then re-seeded. This procedure led to ablation of mCAR1 protein at the cell surface 2 days after transduction (Figure 4a and b). In contrast, control cells rapidly re-expressed mCAR1 (Figure 4b). Two days after AdshCAR4m treatment, a few cells still displayed some membrane-associated mCAR1 immunoreactivity (Figure 4b), probably reflecting residual mCAR1 domains still anchored in the cell membrane after trypsinization. At days 3 and 4 after AdshCAR4m transduction, mCAR1 immunoreactivity disappeared from HL-1 cells, whereas it remained permanently detectable in the control cells (Figure 4b). Interestingly, CAR was expressed only at cell-to-cell contact sites in HL-1 cells, suggesting that the observed stability of CAR in intact monolayers is determined by homophilic or heterophilic CAR interaction at cell-to-cell contact sites. Together, the results indicate that AdshCAR4m treatment efficiently inhibits the de novo synthesis of mCAR1.

**Inhibition of CoxB3 replication in HL-1 cells by AdshCAR4m**

The antiviral effect of mCAR1 silencing was now investigated with respect to CoxB3 for which cellular CAR constitutes the internalization receptor. For this purpose, we first investigated the CoxB3 protective efficacy of AdshCAR4m as a function of dose, at an MOI of AdshCAR4m ranging from 10 to 100, using the same trypsin-involving experimental procedure as described above. HL-1 cells were infected with CoxB3 48 h after transduction with AdshCAR4m and the amount of newly generated progeny virus was determined 6 days later. Virus plaque assays clearly demonstrated that CoxB3 replicates in HL-1 cells, but at a rather low frequency because no cytopathogenic effect was visible during the 6-day investigation period. As expected, the strongest reduction of CoxB3 progeny virus production by 97% was observed at the highest AdshCAR4m dose.
with an MOI of 100. Nevertheless, MOIs of 50 and 25 still led to significant inhibition of CoxB3 replication by 85 and 75%, respectively, whereas an MOI of 10 showed no significant effect (Figure 5a).

To investigate whether disruption of pre-existing CAR affects CoxB3 infections, we either treated HL-1 cells with the trypsin-involving experimental procedure described above, or omitted the trypsinization step after AdshCAR4m transduction. The titers of CoxB3 progeny virus generated 5 and 6 days after CoxB3 infection were reduced strongly by about 97% in AdshCAR4m-transduced cells, irrespective of whether membrane-associated CAR was disrupted by trypsinization or not (Figure 5b). These experiments indicate that AdshCAR4m inhibits CoxB3 replication in HL-1 cells with high efficacy. Moreover, proteolysis of membrane-associated CAR apparently does not affect CoxB3 infection.

**Inhibition of adenovirus infections of HL-1 cells by AdshCAR4m**

CAR is also involved in adenovirus infection as an attachment receptor. To investigate the long-term efficacy of AdshCAR4m, with respect to the inhibition of
adenovirus infections and to examine whether proteolysis of pre-existing CAR affects adenovirus infections, HL-1 cells were transduced with AdshCAR4m versus control vector at an MOI of 100. After 24 h, cells were either trypsinized and re-seeded, or the medium was simply changed (treatment without trypsinization). Cells were infected with a luciferase marker adenovirus (MOI of 5) 2–5 days after transduction. The measurement of luciferase activity 24 h later revealed persistent reduction of marker gene expression of about 75% in AdshCAR4m-treated HL-1 cells during the 5-day investigation period. This clearly demonstrates that CAR-shRNA treatment inhibits adenovirus uptake into HL-1 cells, but markedly less efficient than for CoxB3. Inhibition of adenovirus infections was closely similar between trypsinized and non-trypsinized cells (Figure 6) indicating that proteolysis of CAR does not affect the function of CAR in adenovirus infections.

**Anti-adenovirus and anti-CoxB3 effects of CAR silencing in PNCMs**

As HL-1 cells is a permanent heart-derived cell line, we were also interested in investigation of the effects of CAR silencing upon viral infections of primary cardiac cells. For this reason, PNCMs were transduced with AdshCAR2m, whose shRNA sequence completely matches with mouse and rat CAR sequences, or with the control vector AdshGFP, both at an MOI of 100. At this dose, nearly 80% of PNCMs were transduced with AdV (not shown), which is closely similar to the HL-1 cells. Following the treatment of PNCMs with AdshCAR2m, CAR expression was unaffected up to day 3 after transduction, but became strongly downregulated on days 6 and 8 after transduction (Figure 7a). As a consequence of this delayed CAR downregulation, challenge of AdshCAR2m-treated PNCMs with CoxB3 (MOI of 1) resulted in delayed inhibition of CoxB3 replication. In fact, significant reduction of CoxB3 replication was seen only if PNCMs were infected with CoxB3 on days 6 and 8 but not on day 3 after AdshCAR2m treatment. The degree of CoxB3 inhibition was strongly dependent on the AdshCAR2m dose. At an MOI of 100, the AdshCAR2m treatment led to reduction of CoxB3 titers by 66 and 90%, whereas at an MOI of 25, CoxB3 titers were reduced by only 16 and 34% on days 6 and 8, respectively (Figure 7b). Similar results were obtained when AdshCAR2m-transduced PNCMs (MOI of 100) were infected with adenovirus. Its uptake was reduced by 85 and 92%, respectively, on days 6 and 8 after AdshCAR2m transduction, whereas no effect was seen on day 3 (Figure 7c).

**Discussion**

CoxB3 and adenoviruses are common agents of acute myocarditis and inflammatory cardiomyopathy. Although interferon-β treatment has the potential to eliminate cardiotropic viruses and to improve heart function in patients with myocardial persistence of viral genomes, no specific treatment against CoxB3 and adenovirus infections is available to date. With respect to antiviral therapy, RNAi is a promising new technology. Its therapeutic potential against viral infections has been demonstrated in multiple *in vitro* and *in vivo*...
Antiviral efficacy of CAR silencing by RNA interference

H. Fechner et al.

Figure 7 Inhibition of CoxB3 and adenovirus infection in PNCMs by CAR silencing. (a) Detection of rat CAR downregulation by Western blot analysis. PNCMs were transduced with AdshCAR2m or the control vector AdshGFP (each at an MOI of 100) for 3, 6 and 8 days and then investigated for CAR expression using the polyclonal rabbit anti-CAR antibody H-300. (b) PNCMs were transduced with AdshCAR2m or the control vector AdshGFP (at MOIs of 25, 50 and 100) for 3, 6 and 8 days and then infected with CoxB3 (MOI of 1). Cells were harvested 3 days later and CoxB3 titers were determined by plaque assay. Asterisks indicate significant differences ($P < 0.05$). (c) PNCMs were transduced with AdshCAR2m or the control vector AdshGFP (each at an MOI of 100) for 3, 6 and 8 days and then transduced with a luciferase marker adenovirus (MOI of 5). Luciferase expression was measured 24 h later. Asterisks indicate significant differences ($P < 0.005$).

studies.5–7,13–15 Despite encouraging results, however, several reports have revealed a fundamental general problem of siRNA-based antiviral therapy. Owing to the requirement for strict sequence-specificity between therapeutic siRNA and target mRNA, even single point mutations in the viral target sequence may result in the rapid selection of escape mutants during persistent viral infections.17–19

In this study, we show that inhibition of CoxB3 and adenovirus infections is possible via silencing of the CAR receptor by means of vector-generated CAR-shRNA. This strategy is an attractive alternative to siRNA-based silencing of virus-encoded gene, because it drastically reduces the probability of escape mutant development.22 In contrast to previous work,16 our investigations were carried out in myocardial cells representing the actual targets for CoxB3 and adenovirus infections in acute myocarditis and inflammatory cardiomyopathy.23 Treatment of HL-1 cells with the shCAR vector led to efficient and stable removal of mCAR protein from the cell surface, and consequently, to significant inhibition of CoxB3 and adenovirus infection of these cells. Remarkably, adenovirus internalization was reduced by only $\approx 75\%$ despite the near-complete silencing of mCAR expression, whereas CoxB3 infection was inhibited by up to $97\%$. In contrast, CAR silencing in PNCMs resulted in strong inhibition of both adenovirus and CoxB3 infections (by 92 and 90\%, respectively). Adenovirus binding to cells is not exclusively mediated by CAR. Type 2 and 5 adenoviruses use CAR to attach to the cell surface,23 whereas its internalization occurs through $x_{\alpha} / \beta_1$, $x_{\alpha} / \beta_3$, and $x_{\beta_3}$ integrin.29,34,35 Others have shown that heparan sulfate glycosaminoglycans and major histocompatibility complex class I molecules may also be involved in the binding of adenoviruses 2 and 5.36,37 Moreover, the expression of receptors involved in adenovirus infections is highly variable between different cell types and tissues.38 Thus, variable receptor expression levels and interactions of adenoviruses with cell type-specifically expressed alternative receptors are the most likely explanation for the failure of complete CAR silencing to achieve efficient blockade of adenovirus infection in HL-1 cells. To enhance efficacy in inhibition of adenovirus infection via the anti-receptor approach, it seems to be necessary to simultaneously inhibit CAR and its co-receptors.

In contrast to the anti-adenovirus experiments, the anti-CAR approach was efficient with respect to CoxB3 in both HL-1 cells and PNCMs. The magnitude of inhibition of CoxB3 infection correlated well with the vector-induced ablation of mCAR from the cell surface and emphasizes the key role of CAR in CoxB3 infections of cardiac cells. The molecular reason for the differences of anti-CAR treatment in adenovirus versus CoxB3 infections may be the unique role played by CAR during CoxB3 infection as it induces conformational changes in the virus capsid that are essential for CoxB3 entry into the target cell.27 The high efficacy of the shCAR vector against this virus indicates that CAR silencing is a promising therapeutic approach against CoxB3 infections of the myocardium. Previous studies have shown a similar degree of inhibition when using siRNAs directed against CoxB3 viral genomic RNA or its RNA intermediate.14,15,39 Combination of direct antiviral approaches, which are prone to escape mutant development with the current anti-receptor strategy, is likely to further increase the efficacy of RNAi-based antiviral therapy.

Recently, it has been shown that silencing of CAR by chemically synthesized siRNA inhibited CoxB3 infection in human cells of non-cardiac origin.27 However, this approach decreased virus titers by only $\approx 60\%$,27 which is markedly less than in the present study employing AdV-generated shCARs. This difference should be the result of high transduction efficacy of AdVs and the prolonged high-level expression of the shCAR. A bottleneck of chemically synthesized siRNAs is its transient silencing activity of $\approx 3$ days in cardiac cells.28 Viral vectors expressing shRNAs, however, enable long-term silencing of target genes in cells of cardiac origin40 and allow efficient delivery of transgenic sequences to the heart.41,42 Among the currently available viral vectors, pseudotyped AAV9 vectors appear to be most promising for cardiac gene therapy as they allow highly efficient
targeted transduction of the heart by way of simple intravenous injection. CAR is a cell adhesion protein mediating homotypic and heterotypic intercellular interactions. It is a component of specialized intercellular junctions including epithelial tight junctions, neuro-muscular junctions and myocardial intercalated discs. We found it to be localized exclusively at cell-to-cell contact sites between HL-1 cells, possibly as a consequence of cell membrane-associated CAR stabilization through homotypic (CAR-CAR) or heterotypic (CAR-protein) intercellular protein interactions. In contrast to previous CAR silencing attempts using synthetic siRNAs, the newly developed viral vectors AdshCAR4m and AdshCAR2m achieved near complete and stable knockout of CAR. This was an essential prerequisite to reveal significantly different kinetics of CAR protein ablation in different cell types, in particular, an unexpectedly high stability of CAR in primary cells versus a stable cell line. These data may be explained by cell type-specific CAR protein kinetics, but differential CAR-mRNA stability or CAR-shRNA processing through the cellular microRNA/shRNA machinery also need to be taken into account. The delayed downregulation of CAR following vector-mediated CAR-shRNA delivery in primary cardiomyocytes is relevant for in vivo investigations because the time lag between vector application and CAR silencing needs to be considered in the development of antiviral therapy protocols.

An important concern associated with downregulation of a cellular receptor molecule for antiviral therapy are the possible side effects resulting from ablation of the normal cellular functions of the receptor. During organogenesis, CAR is highly expressed in the heart, but rapidly downregulated post partum. In a recently published genomic mouse knockout model, cardiomyocyte-specific CAR deletion resulted in severe cardiac anomalies and death between days 11.5 and 13.5 of embryonal development. If the CAR gene became ablated late in embryonic development, however, the CAR-deficient animals survived into adulthood and had no evident cardiac anomalies. This finding suggests that CAR silencing by RNAi, as employed in our study, should be well tolerable over considerable periods of time, during which virus migration and spreading were efficiently inhibited. Furthermore, treatment of HL-1 cells with AdV-generated shCAR revealed no side effects as we found no changes in cell growth, cell morphology or F-actin cytoskeleton protein expression (not shown). As CAR is a component of tight junctions and may play a permanent role in tissue function of several organs, further experiments have to examine if CAR knockdown by RNAi has no side effects in vivo even over prolonged treatment times.

In summary, high efficacy of CAR gene silencing by shRNAs in cardiac-derived cells was observed against CoxB3, whereas cell type-dependent results were obtained against adenovirus. In contrast to previous silencing attempts using siRNAs or shRNA-plasmid, the newly developed shRNA vectors were able to achieve nearly complete and stable knockout of CAR transcription. This, in turn, revealed significantly different responses of cellular CAR protein to CAR-shRNA treatment, which need to be considered as important determinants of this new antiviral approach in vivo.

Materials and methods

Cell cultures

The HL-1 cell line, a cardiac muscle cell line established from an AT-1 mouse atrial cardiomyocyte tumor lineage, was a kind gift from William C Claycomb. The cells were maintained in Claycomb medium supplemented with 10% fetal calf serum (FCS) (JRH Bioscience, Lenexa, USA), 1% each of penicillin and streptomycin, 0.1 mM norepinephrine (Sigma, München, Germany) and 2 mM l-glutamine (Invitrogen, Karlsruhe, Germany). HeLa (human cervical carcinoma) cells, HEK293 (human embryonal kidney) and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco BRL, Karlsruhe, Germany) supplemented with 10% FCS and 1% penicillin/streptomycin. PNCMs were generated and maintained as described previously.

Construction of expression plasmids

For each mCAR-shRNA, four short oligonucleotides that cover antisense, loop and sense sequence of the shRNA were synthesized (Oligoservice, Berlin, Germany). The target sequence of shCAR2m and shCAR3m encompassed 19 nucleotides, and that of shCAR4m 21 nucleotides (see Figure 1). The forward and reverse oligos were phosphorylated by T4 polynucleotide kinase (New England Biolabs, Frankfurt, Germany), annealed and cloned into HindIII/BamHI-digested pSilencerTM 2.1-U6 neo (Ambion, Austin, TX, USA). The shRNA expression cassettes were then cloned into pAdshPLB48 via EcoRI/HindIII to yield the plasmids pAdshCAR2m, pAdshCAR3m, and pAdshCAR4m.

For the generation of the mCAR1 expression plasmid pAdmCAR1, total RNA was first isolated from HL-1 cells and reverse-transcribed by the use of SuperScriptII reverse transcriptase (Invitrogen). The mCAR1-cDNA was then amplified using the primer pair MACAR105s (5'-CGCGAGCAGCAGCATGGGCCC3') and HCAR-1157 (5'-CTATAGATGAGATCACTCTG3') in a 35-cycle PCR with Pwo polymerase (Roche, Mannheim, Germany), and the resulting fragment was then cloned in the pCR2.1-TOPO vector (Invitrogen). An EcoRI fragment containing mCAR1-cDNA was excised and inserted into the shuttle plasmid pZS2. For generation of the recombinant mCAR2 expression plasmid pAdmCAR2, the mCAR2 cDNA was excised from pCR3.1-mCAR2 with HindIII/Pmel and cloned into pZS2 via Smal/HindIII. Correctness of all plasmids was proven by sequencing on an ABI 310 genetic analyzer (Applied Biosystems, Foster city CA, USA).

Development of AdVs

The adenoviral shuttle plasmids pAdshCAR4m and pAdshCAR2m were linearized with SphI and ligated to the 5' 'long arm' of the XbaI-digested E1 E3 adenovirus mutant R55, transfected in HEK293 cells and propagated as described. This resulted in the AdVs AdshCAR4m, AdshCAR4m, and AdshPLB. An additional shGFP expressing AdV (AdshGFP) containing an siRNA target sequence (5'-GGTTATGTACAGGAACGCA3') directed against GFP was generated in the same way as AdshCAR4m and AdshCAR2m. The AdVs Ad5CMV-GFP, Ad5CMV-Ubc and Ad5shPLB, have been described. All AdVs were tested for possible RCA contamination by
PCR as described.\textsuperscript{53} Virus titers were determined by standard plaque assays on HEK293 cells.

**Plasmid transfections**

Plasmid transfections were carried out by calcium phosphate precipitation. Cells were seeded in six-well plates at a density of 5 × 10\textsuperscript{5} cells/well and transfected with 1 \( \mu \)g of each plasmid/well in 250 \( \mu \)l HBs buffer, pH 7.1 and 250 \( \mu \)l 0.25 M CaCl\(_2\) in the presence of DMEM containing 10\% FCS. After 24 h, cells were washed three times with phosphate-buffered solution (PBS) and supplied with fresh growth medium.

**Northern blots**

Total RNA was isolated with TRIzol Reagent (Invitrogen) following the manufacturer's instruction. Ten micrograms of isolated RNA was electrophoretically separated on 1\% formaldehyde agarose gels. After transfer to a Hybond N nylon membrane (Amersham, Buckinghamshire, UK), the membranes were hybridized with a single-stranded (ss) antisense mCAR1-specific DNA probe using the mCAR1-cDNA excised from pAdm-CAR1 as template. Rehybridization to control for equal DNA loading was carried out with an ss-antisense \( \beta \)-actin-specific DNA probe as described,\textsuperscript{55} using a PCR fragment amplified from HeLa cells with the primer pair 5'-AAGGATTCTTATGTGGTCG-3' and 5'-CTCCTTAATGTCCAGCAGA-3'. The labeling of the probes with \([\alpha^32P]dCTP\) in a PCR-like reaction was described.\textsuperscript{39} Hybridized filters were exposed to Kodak Biomax MS film (Integra Biosciences, Fernwald, Germany) and hybridization signal intensity was then determined by phosphoimaging in a Fuji Film BAS-1500 imager (Fuji Photo Film, Dusseldorf, Germany).

**Flow cytometry**

To determine the fraction of cells transduced by an AdV, HL-1 cells were seeded in a six-well plate at a density of 4 × 10\textsuperscript{5} cells/well. After 24 h, the cells were transduced with different MOI of adenoviral GFP marker vector (Ad5CMVGFP).\textsuperscript{38} Flow cytometry was performed 48 h later on a FACS Calibur with CellQuest software (Becton Dickinson, Franklin Lakes, NJ, USA).

**Quantitative real-time reverse transcription-PCR**

Total RNA from HL-1 cells was isolated with RNAzol. Four micrograms of RNA was incubated with peqGOLD DNasel (Peqlab, Erlangen, Germany) at 37°C for 30 min. The reaction was stopped by addition of 2.5 \( \mu \)l of 25 mM ethylenediaminetetraacetic acid (EDTA) and heating for 15 min to 65°C. RNA was reverse-transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems) according to the manufacturer's instruction. For the quantification of gene expression, quantitative PCR assay was performed on a Mastercycler ep Gradient S (Eppendorf) with TaqMan Universal Master Mix UNG (Applied Biosystems) using the standard conditions determined by the company. After AmpliTaqGold activation for 10 min at 95°C, 40 cycles were run at a denaturing temperature of 95°C (15 s) and an annealing/extension temperature of 60°C (1 min). A unique combination of forward and reverse primers and fluorescent MGB probes designed by the company was used for the mCAR1 target gene, and the HPRT and GAPDH housekeeping genes, respectively, which were used for normalization. cDNA corresponding to 50 ng of RNA was used per 20 \( \mu \)l reaction and each reaction was performed in triplicate. The level of expression was calculated on the basis of the PCR cycle number (\( C_t \)) at which the exponential growth in fluorescence from the probe passes a certain threshold value. Relative expression (\( \Delta C_t \)) was determined by the difference in the \( C_t \) values for the target gene after normalization to RNA input level, using HPRT \( C_t \) values. Relative quantification was determined by standard \( 2^{-\Delta \Delta C_t} \) calculation in percent.

**Assessment of cellular shCAR4 expression levels**

Semi-quantitative analysis of shCAR4\textsubscript{m} expression included two steps: an RT reaction containing 50 ng/\( \mu \)l total RNA samples, 50 nM shCAR4 stem–loop RT primer (5'-GTCTGATTCAGTGCTCCGGAGTATTCCA-3'), 1 RT buffer (Applied Biosystems), 0.25 mM each of dNTP, 3.33 U/\( \mu \)l MultiScribe reverse transcriptase (Applied Biosystems) and 0.25 U/\( \mu \)l RNase inhibitor (PeqLab). The 7.5 \( \mu \)l reactions were incubated for 30 min at 16°C, 30 min at 42°C, 5 min at 85°C and then held at 4°C. The 20 \( \mu \)l PCR reactions included 1 \( \mu \)l of RT product, 1 \( \times \) Gene Amp PCR buffer and 1.25 U AmpliTaq DNA polymerase (Roche), 0.25 mM each of dNTP and 1.5 \( \mu \)M forward primer (5'-CGCGCCGATCCAGAAGATGTTA-3') and reverse primer (5'-GTCGAGGTTCGGAGAAGATT-3') specific for shCAR4\textsubscript{m} cDNA. The reactions were incubated in a Gene Amp PCR System 9700 (Applied Biosystems) at 95°C for 5 min, followed by 30 cycles at 95°C for 15 s and 60°C for 1 min and analyzed by gel electrophoresis. Alternatively, shCAR4\textsubscript{m} quantification was carried out by real-time PCR. The TaqMan reactions contained 1 \( \times \) TaqMan Universal PCR Master Mix (Applied Biosystems), 1 \( \mu \)l of RT product, 200 nM forward primer, 200 nM reverse primer and Sybr Green (Invitrogen) at 1:10 000. The labeling of the PCR fragment amplified from HeLa cells with the primer pair 5'-GCGGCGGATCGGGAAGAGATT-3' and 5'-CTCCTTAATGTCCAGCAGAGA-3' was incubated with anti-CAR polyclonal antibody H-300 (Bio-Rad, Hercules, CA, USA). Subsequently, the membrane was incubated with anti-rabbit antibodies conjugated with peroxidase (DAKO, Hamburg, Germany) and chemiluminescence was achieved by using an enhanced chemiluminescence system (Amersham Biosciences).

**Western blots**

Cells were solubilized in general lysis buffer (20 mM Tris, pH 8, 10 mM NaCl, 0.5% (v/v) Triton X-100, 5 mM EDTA, 3 mM MgCl\(_2\)). After boiling of the lysate at 95°C for 5 min, proteins were separated on NuPAGE 4–12% Bis-Tris gels (Invitrogen) under denaturing and reducing conditions and transferred onto a PVDF membrane (Bio-Rad, Hercules, CA, USA). Subsequently, the membrane was incubated with anti-CAR polyclonal antibody H-300 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h in dry milk. Secondary swine-anti-rabbit antibodies conjugated with peroxidase (DAKO, Hamburg, Germany) were used at 1:10 000 dilution. Detection by chemiluminescence was achieved by using an enhanced chemiluminescence system (Amersham Biosciences).

**Indirect immunofluorescence**

HL-1 cells were fixed with 1 ml of Tris-buffered solution (TBS) containing 4% formaldehyde and permeabilized by 0.5% Triton X-100. After blocking in TBS buffer with
5% FCS and 0.1% Triton X-100, cells were incubated with anti-mCAR1 rabbit polyclonal antibody RP-291® diluted 1:100 in blocking solution for 1 h. After extensive rinsing, the cells were incubated with a biotin-labeled donkey–anti-rabbit secondary antibody (Dianova, Hamburg, Germany) at a dilution of 1:400 for 1 h. Cells were subsequently incubated with Cy3-conjugated streptavidin (Dianova) (dilution 1:500) for 30 min and nuclei were stained with 4,6-diamidino-2-phenylindole (0.5 μg/ml) (Sigma). After covering with Fluoromount GTM (Southern Biotechnology, Birmingham, AL, USA), images were taken by using an Olympus BX60 immunofluorescence microscope.

**Luciferase assays**

Luciferase assays were performed using the luciferase reporter gene assay kit (Roche) following the manufacturer’s instructions. Briefly, cells were washed twice with PBS buffer and lysed directly by adding 250 μl of cell lysis reagent and incubating for 15 min at room temperature. Cell debris was pelleted in a microfuge at maximum speed for 15 s and 10 μl of the supernatant was then transferred to a 5-ml tube (Sarstedt, Nürnberg, Germany). Luciferase substrate (50 μl) was added and the luciferase activity was immediately measured in a Lumat LB 9501 luminometer (Berthold, Bad wildbad, Germany).

**Viruses plaque assays**

HeLa cells were cultured in six-well cell culture plates as confluent monolayers at a density of 1.2 × 10⁴ cells/well and incubated at 37°C in Eagle’s MEM (minimal essential medium) with 5% (v/v) FCS under 5% (v/v) CO₂. After 24 h, cells were overlaid with 1 ml of diluted supernatant from HL-1 cells, which were treated by three freeze/thaw cycles to release intracellular CoxB3 virus. The HeLa cell culture was then incubated at 37°C for 30 min, the supernatant removed and the cells overlaid with 2 ml agar containing Eagle’s MEM. Three days later, cells were stained with 0.025% (w/v) neutral red. The virus titer was determined by plaque counting 3 h after staining. Mean and standard deviation were calculated from two independent experiments, each performed in duplicate.

**Statistical analysis**

To test for statistical significance, Student’s t-test was applied. A value of P < 0.05 was considered statistically significant.

**Abbreviations**

AdV, adenoviral vector; CAR, coxsackievirus–adenovirus-receptor; CoxB3, coxsackievirus B3; PNCMs, primary neonatal rat cardiomyocytes; RNAi, RNA interference; shCAR, shRNA against CAR; shRNA, short hairpin RNA; siRNA, short interfering RNA.

**Acknowledgements**

This work was supported by Deutsche Forschungsge- meinschaft through grants SFB-TR-19/CS to WP and HF and SFB-TR-19/C1 to JK. We thank Denise Werk for generating the shRNA expression cassette against hCAR.

**References**

1. Bowles NE, Richardson PJ, Olsen EG, Archard LC. Detection of Coxackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. *Lancet* 1986; 1: 1120–1123.

2. Bowles NE, Ji J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R et al. Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults. *J Am Coll Cardiol* 2003; 42: 466–472.

3. Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. *Circulation* 2005; 112: 1965–1970.

4. Poller W, Kuhl U, Tschoepe C, Pauschinger M, Fechner H, Schultheiss HP. Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy. *J Mol Med* 2005; 83: 579–586.

5. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. *Nat Med* 2005; 11: 50–55.

6. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H et al. Inhibition of hepatitis B virus in mice by RNA interference. *Nat Biotechnol* 2003; 21: 639–644.

7. Carmona S, Ely A, Crowther C, Mooila N, Salazar FH, Marion PL et al. Effective inhibition of HBV replication in vivo by anti-HBs short hairpin RNAs. *Mol Ther* 2006; 13: 411–421.

8. Takigawa Y, Nagano-Fujii M, Deng L, Hidajat R, Tanaka M, Mizuta H et al. Suppression of hepatitis C virus replication by RNA interference directed against the NS3 and NS5B regions of the viral genome. *Microbiol Immunol* 2004; 48: 591–598.

9. Chen W, Liu M, Jia Y, Yan W, Wei X, Chen J et al. Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo. *J Virol* 2006; 80: 3559–3566.

10. Yoon JS, Kim SH, Shin MC, Hong SK, Jung YT, Khang IG et al. Inhibition of herpesviruses-6B RNA replication by short interference RNAs. *J Biol Chem* 2004; 37: 383–385.

11. Wiebusch L, Truss M, Hagemeier C. Inhibition of human cytomegalovirus replication by small interfering RNAs. *J Virol* 2004; 88: 179–184.

12. Lu A, Zhang H, Zhang X, Wang H, Hu Q, Shen L et al. Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting SARS-dependent RNA polymerase. *Virology* 2004; 324: 84–89.

13. Park WS, Hayafune M, Miyano-Kurosaki N, Takaku H. Specific HIV-1 env gene silencing by short interfering RNAs in human peripheral blood mononuclear cells. *Gene Therapy* 2003; 10: 2046–2050.

14. Merl S, Michaelis C, Jaschke B, Vorpahl M, Seidl S, Wessely R. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. *Circulation* 2005; 111: 1583–1592.

15. Werk D, Schubert S, Lindig V, Grunert HP, Zeichhardt H, Erdmann VA et al. Developing an effective RNA interference strategy against a plus-strand RNA virus: silencing of coxsackievirus B3 and its cognate coxsackievirus-adenovirus receptor. *Biol Chem* 2005; 386: 857–863.

16. Sabariego S, Gimenez-Barcons M, Tapia N, Clotet B, Martinez MA. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. *J Virol* 2006; 80: 571–577.

17. Wilson JA, Richardson CD. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. *J Virol* 2005; 79: 7050–7058.
18 Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003; 77: 11531–11535.

19 Gitlin L, Stone JK, Andino R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J Virol 2005; 79: 1027–1035.

20 Murray JL, Mavrakis M, McDonald NJ, Yilla M, Sheng J, Bellini WJ et al. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J Virol 2005; 79: 11742–11751.

21 Anderson J, Akkina R. HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2005; 2: 1.

22 Arrighi JF, Pion M, Wiznowericz M, Geijtenbeek TB, Garcia E, Abraham S et al. Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. J Virol 2004; 78: 10848–10855.

23 Gao X, Wang H, Saireni J. Inhibition of Epstein–Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells. J Virol 2004; 78: 11798–11806.

24 Ping YH, Chu CY, Cao H, Jacque JM, Stevenson M, Rana TM. Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. Retrovirology 2004; 1: 46.

25 Kameoka M, Nukuzuma S, Itaya A, Tanaka Y, Ota K, Ikuta K et al. RNA interference directed against poly(ADP-ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J Virol 2004; 78: 8931–8934.

26 Bergelson JM, Kriithivas A, Celi L, Droguett G, Horwitz MS, Wickham T et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72: 415–419.

27 Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 2006; 124: 119–131.

28 Watanabe A, Araie M, Yamazaki K, Koitabashi N, Wuytack F, Kurabayashi M. Phospholamban ablation by RNA interference increases Ca++ uptake into rat cardiac myocyte sarcoplasmic reticulum. J Mol Cell Cardiol 2004; 37: 691–698.

29 Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352–3356.

30 Reynolds A, Leake D, Boese Q, Scarringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 22: 326–330.

31 Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Loher C, Tomko RP, Xu R, Philipson L, Kriithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.

32 Wickham TJ, Mathias P, Cheresk DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309–319.

33 Kandolf R. Virus etiology of inflammatory cardiomyopathy. Dtsch Med Wochenschr 2004; 129: 2187–2192.

34 Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Kriithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Circulation 2001; 103: 211–218.

35 Fechner H, Tuckau L, Kurosek I, Sipos I, Wang X, Pinkert S et al. Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban. Gene Therapy 2007; 14: 211–218.

36 Krithivas A, Hong JS, Isolation of a common receptor for coxsackie B viruses and adenoviruses. Proc Natl Acad Sci USA 1997; 94: 3352–3356.

37 Deecherki MC, Tamanini A, Bonizatto A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000; 268: 382–390.

38 Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Loher C, Tomko RP, Xu R, Philipson L, Kriithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Circulation 2001; 103: 211–218.
ventricle and abnormalities of sinuatrial valves. Circ Res 2006; 98: 923–930.

52 Dorner AA, Wegmann F, Butz S, Wolburg-Buchholz K, Wolburg H, Mack A et al. Coxsackievirus-adenovirus receptor (CAR) is essential for early embryonic cardiac development. J Cell Sci 2005; 118: 3509–3521.

53 Fechner H, Wang X, Wang H, Jansen A, Pauschinger M, Scherubl H et al. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Therapy 2000; 7: 1954–1968.

54 Marienfeld U, Haack A, Thalheimer P, Schneider-Rasp S, Brackmann HH, Poller W. ‘Autoreplication’ of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes. Gene Therapy 1999; 6: 1101–1113.

55 Sipo I, Hurtado Pico A, Wang X, Eberle J, Petersen I, Weger S et al. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. J Mol Med 2006; 84: 215-225.

56 Sollerbrant K, Raschberger E, Mirza M, Engstrom U, Philipson L, Ljungdahl PO et al. The Coxsackievirus and adenovirus receptor (CAR) forms a complex with the PDZ domain-containing protein ligand-of-numb protein-X (LNX). J Biol Chem 2003; 278: 7439–7444.